SCHEMBL29506475

SCHEMBL29506475

Cc1cc(Nc2ncc3c(n2)N2CCN=C2N(c2c(C)cccc2F)C3=O)ccc1N1CCN(C)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 5/20 0.57
▸ TNK2 Q07912 3/20 0.50
▸ JAK2 O60674 3/20 0.47
▸ SRC P12931 2/20 0.47
▸ EGFR P00533 5/20 0.46
▸ CSF1R P07333 4/20 0.46
▸ FLT3 P36888 2/20 0.46
▸ JAK3 P52333 3/20 0.44
▸ SIK1 P57059 2/20 0.44
▸ SIK2 Q9H0K1 2/20 0.44
▸ SIK3 Q9Y2K2 2/20 0.44
▸ AXL P30530 2/20 0.44
▸ BRD4 O60885 1/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ BRDT Q58F21 1/20 0.43
▸ KDR P35968 2/20 0.43
▸ CDC7 O00311 1/20 0.43
▸ PLK4 O00444 1/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ AURKA O14965 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21373275 1.00 WEE1 (0.57) WEE1TNK2JAK2SRCEGFR
SCHEMBL29506445 0.97 WEE1 (0.59) WEE1TNK2JAK2SRCEGFR
SCHEMBL21373336 0.97 WEE1 (0.59) WEE1TNK2JAK2SRCEGFR
SCHEMBL21373399 0.94 WEE1 (0.60) WEE1TNK2JAK2SRCFLT3
SCHEMBL29506490 0.94 WEE1 (0.60) WEE1TNK2JAK2SRCFLT3
SCHEMBL21373447 0.93 WEE1 (0.65) WEE1TNK2JAK2SRCEGFR
SCHEMBL29506571 0.93 WEE1 (0.65) WEE1TNK2JAK2SRCEGFR
SCHEMBL21373360 0.92 WEE1 (0.56) WEE1TNK2JAK2SRCEGFR
SCHEMBL29506542 0.92 WEE1 (0.56) WEE1TNK2JAK2SRCEGFR
SCHEMBL21373347 0.92 WEE1 (0.65) WEE1TNK2JAK2SRCEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN claimed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN claimed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO claimed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO claimed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN claimed
WO-2025074275-A1 COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS AND WEE1 INHIBITORS REPARE THERAPEUTICS, INC. (CA) 2025-04-10 — — WO disclosed
CN-118338905-A Use of Wee1 kinase inhibitors in the treatment of cancer 上海瑛派药业有限公司 2024-07-12 — — CN disclosed
CN-117202908-A Use of Wee1 kinase inhibitors in the treatment of cancer diseases 上海瑛派药业有限公司 2023-12-08 — — CN disclosed
WO-2023093840-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2023-06-01 — — WO disclosed
WO-2022188802-A1 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) 2022-09-15 — — WO disclosed
CN-109906227-B 8, 9-dihydroimidazo [1,2-a ] pyrimido [5,4-e ] pyrimidin-5 (6H) -ones 上海瑛派药业有限公司 2022-03-11 — — CN disclosed
Send feedback